© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Follicular Lymphoma
Copanlisib Combo Prolongs PFS in Phase 3 Study of Indolent Non-Hodgkin Lymphoma
October 15, 2020
The primary end point of prolonged progression-free survival in the phase 3 CHRONOS-3 study was met with copanlisib in combination with rituximab as treatment of patients with indolent non-Hodgkin lymphoma.
Tazemetostat Monotherapy Generates Durable Responses in Heavily Pretreated Follicular Lymphoma
October 13, 2020
Tazemetostat as a single agent demonstrated clinically meaningful durable responses as treatment of patients with heavily pretreated relapsed/refractory follicular lymphoma.
FDA to Review sBLA for Axi-Cel in R/R Follicular Lymphoma and Marginal Zone Lymphoma
September 05, 2020
The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.
Doctors Debate: Should Asymptomatic Patients With Follicular Lymphoma Be Actively Monitored With Watch-and-Wait Strategy or Immediately Treated?
September 01, 2020
The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.
Lenalidomide/Rituximab Induction as Effective as Rituximab Plus Chemo in Follicular Lymphoma Subset
August 04, 2020
Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).
Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point
August 04, 2020
Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
Tazemetostat Approval Addresses Unmet Need in Relapsed/Refractory Follicular Lymphoma
June 26, 2020
In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.
FDA Approves Tazemetostat for Relapsed/Refractory Follicular Lymphoma
June 18, 2020
"The durable responses observed with this drug are notable in the context of the safety profile and route of oral, at-home administration, and will offer an important new option for physicians as we care for patients with relapsed/refractory follicular lymphoma."
Rolling NDA Submitted to FDA for Umbralisib as Treatment of Marginal Zone, Follicular Lymphomas
June 17, 2020
“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."